Search

Your search keyword '"Copelan E"' showing total 448 results
Start Over Author "Copelan E"
448 results on '"Copelan E"'

6. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Author

Bachanova, V, Marks, D I, Zhang, M-J, Wang, H, de Lima, M, Aljurf, M D, Arellano, M, Artz, A S, Bacher, U, Cahn, J-Y, Chen, Y-B, Copelan, E A, Drobyski, W R, Gale, R P, Greer, J P, Gupta, V, Hale, G A, Kebriaei, P, Lazarus, H M, Lewis, I D, Lewis, V A, Liesveld, J L, Litzow, M R, Loren, A W, Miller, A M, Norkin, M, Oran, B, Pidala, J, Rowe, J M, Savani, B N, Saber, W, Vij, R, Waller, E K, Wiernik, P H, and Weisdorf, D J

Published
2014
Full Text
View/download PDF

9. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

Author

Hale, G A, Arora, M, Ahn, K W, He, W, Camitta, B, Bishop, M R, Bitan, M, Cairo, M S, Chan, K, Childs, R W, Copelan, E, Davies, S M, Perez, M A D, Doyle, J J, Gale, R P, Vicent, M G, Horn, B N, Hussein, A A, Jodele, S, Kamani, N R, Kasow, K A, Kletzel, M, Lazarus, H M, Lewis, V A, Myers, K C, Olsson, R, Pulsipher, M, Qayed, M, Sanders, J E, Shaw, P J, Soni, S, Stiff, P J, Stadtmauer, E A, Ueno, N T, Wall, D A, and Grupp, S A

Published
2013
Full Text
View/download PDF

11. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, Saber, W, Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, and Saber, W

Published
2021

28. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy.

Author

Epperla, N, Li, A, Logan, B, Fretham, C, Chhabra, S, Aljurf, M, Chee, L, Copelan, E, Freytes, CO, Hematti, P, Lazarus, HM, Litzow, M, Nishihori, T, Olsson, RF, Prestidge, T, Saber, W, Wirk, B, Yared, JA, Loren, A, Pasquini, M, Epperla, N, Li, A, Logan, B, Fretham, C, Chhabra, S, Aljurf, M, Chee, L, Copelan, E, Freytes, CO, Hematti, P, Lazarus, HM, Litzow, M, Nishihori, T, Olsson, RF, Prestidge, T, Saber, W, Wirk, B, Yared, JA, Loren, A, and Pasquini, M

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) was conducted including patients receiving allo-HCT between 2008 and 2016, with the primary objective of evaluating the incidence of TA-TMA. Secondary objectives included identification of risk factors associated with TA-TMA, and the impact of TA-TMA on overall survival and the need for renal replacement therapy (RRT). Among 23,665 allo-HCT recipients, the 3-year cumulative incidence of TA-TMA was 3%. Variables independently-associated with increased incidence of TA-TMA included female sex, prior autologous transplant, primary disease (acute lymphoblastic leukaemia and severe aplastic anaemia), donor type (mismatched or unrelated donor), conditioning intensity (myeloablative), GVHD prophylaxis (sirolimus + calcineurin inhibitor), pre-transplant kidney dysfunction and acute GVHD (time-varying effect). TA-TMA was associated with higher mortality (HR = 3·1, 95% Confidence Interval [CI] = 2·8-16·3) and RRT requirement (HR = 7·1, 95% CI = 5·7-311·6). This study provides epidemiologic data on TA-TMA and its impact on transplant outcomes. Increased awareness of the risk factors will enable providers to be vigilant of this uncommon but serious transplant complication. The results will also provide benchmarking for future study designs and comparisons.

Published
2020

29. Comparison of outcomes of HCT in blast phase of BCR-ABL1(-) MPN with de novo AML and with AML following MDS

Author

Gupta, V, Kim, S, Hu, Z-H, Liu, Y, Aljurf, M, Bacher, U, Beitinjaneh, A, Cahn, J-Y, Cerny, J, Copelan, E, Gadalla, SM, Gale, RP, Ganguly, S, George, B, Gerds, AT, Gergis, U, Hamilton, BK, Hashmi, S, Hildebrandt, GC, Kamble, RT, Kindwall-Keller, T, Lazarus, HM, Liesveld, JL, Litzow, M, Maziarz, RT, Nishihori, T, Olsson, RF, Rizzieri, D, Savani, BN, Seo, S, Solh, M, Szer, J, Verdonck, LF, Wirk, B, Woolfrey, A, Yared, JA, Alyea, EP, Popat, UR, Sobecks, RM, Scott, BL, Nakamura, R, Saber, W, Gupta, V, Kim, S, Hu, Z-H, Liu, Y, Aljurf, M, Bacher, U, Beitinjaneh, A, Cahn, J-Y, Cerny, J, Copelan, E, Gadalla, SM, Gale, RP, Ganguly, S, George, B, Gerds, AT, Gergis, U, Hamilton, BK, Hashmi, S, Hildebrandt, GC, Kamble, RT, Kindwall-Keller, T, Lazarus, HM, Liesveld, JL, Litzow, M, Maziarz, RT, Nishihori, T, Olsson, RF, Rizzieri, D, Savani, BN, Seo, S, Solh, M, Szer, J, Verdonck, LF, Wirk, B, Woolfrey, A, Yared, JA, Alyea, EP, Popat, UR, Sobecks, RM, Scott, BL, Nakamura, R, and Saber, W

Abstract

Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.

Published
2020

39. Allogeneic hematopoietic cell transplant for AML : no impact of pre-transplant extramedullary disease on outcome

Author

Goyal, S. D., Zhang, M-J, Wang, H-L, Akpek, G., Copelan, E. A., Freytes, C., Gale, R. P., Hamadani, M., Inamoto, Y., Kamble, R. T., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Reshef, R., Ritchie, D. S., Saber, W., Savani, B. N., Seber, A., Shea, T. C., Tallman, M. S., Wirk, B., Bunjes, D. W., Devine, S. M., de Lima, M., Weisdorf, D. J., Uy, G. L., Goyal, S. D., Zhang, M-J, Wang, H-L, Akpek, G., Copelan, E. A., Freytes, C., Gale, R. P., Hamadani, M., Inamoto, Y., Kamble, R. T., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Reshef, R., Ritchie, D. S., Saber, W., Savani, B. N., Seber, A., Shea, T. C., Tallman, M. S., Wirk, B., Bunjes, D. W., Devine, S. M., de Lima, M., Weisdorf, D. J., and Uy, G. L.

Abstract

The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (Cl) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P=0.23) or relapse (relative risk= 1.03, 95% CI, 0.92-1.16; P=0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.

Published
2015
Full Text
View/download PDF

41. Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study

Author

Hamilton, B K, primary, Rybicki, L, additional, Haddad, H, additional, Abounader, D, additional, Yurch, M, additional, Majhail, N S, additional, Hanna, R, additional, Sobecks, R, additional, Dean, R, additional, Liu, H, additional, Hill, B, additional, Copelan, E, additional, Bolwell, B, additional, and Kalaycio, M, additional

Published
2015
Full Text
View/download PDF

42. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

Author

Traina, F, primary, Visconte, V, additional, Elson, P, additional, Tabarroki, A, additional, Jankowska, A M, additional, Hasrouni, E, additional, Sugimoto, Y, additional, Szpurka, H, additional, Makishima, H, additional, O'Keefe, C L, additional, Sekeres, M A, additional, Advani, A S, additional, Kalaycio, M, additional, Copelan, E A, additional, Saunthararajah, Y, additional, Olalla Saad, S T, additional, Maciejewski, J P, additional, and Tiu, R V, additional

Published
2013
Full Text
View/download PDF

43. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Author

Bachanova, V, primary, Marks, D I, additional, Zhang, M-J, additional, Wang, H, additional, de Lima, M, additional, Aljurf, M D, additional, Arellano, M, additional, Artz, A S, additional, Bacher, U, additional, Cahn, J-Y, additional, Chen, Y-B, additional, Copelan, E A, additional, Drobyski, W R, additional, Gale, R P, additional, Greer, J P, additional, Gupta, V, additional, Hale, G A, additional, Kebriaei, P, additional, Lazarus, H M, additional, Lewis, I D, additional, Lewis, V A, additional, Liesveld, J L, additional, Litzow, M R, additional, Loren, A W, additional, Miller, A M, additional, Norkin, M, additional, Oran, B, additional, Pidala, J, additional, Rowe, J M, additional, Savani, B N, additional, Saber, W, additional, Vij, R, additional, Waller, E K, additional, Wiernik, P H, additional, and Weisdorf, D J, additional

Published
2013
Full Text
View/download PDF

45. Predictive Factors for Adverse Outcomes After Use of Donor Cell Infusion (DCI) in Patients with Relapsed Hematological Malignancies Treated with Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Author

Bejanyan, N., primary, Bolwell, B., additional, Rybicki, L., additional, Abounader, D., additional, Duong, H., additional, Dean, R., additional, Sobecks, R., additional, Andresen, S., additional, Pohlman, B., additional, Copelan, E., additional, and Kalaycio, M., additional

Published
2012
Full Text
View/download PDF

48. The Impact of the Major Histocompatibility Complex Class I-Related Chain a (Mica) and Human Leukocyte Antigen (HLA)-DP Mismatches on Severe Acute GVHD in Patients Receiving Allogeneic Hematopoietic Progenitor Cell Transplants (AHPCT) from Adult Unrelated Donors

Author

Askar, M., primary, Rybicki, L., additional, Zhang, A., additional, Thomas, D., additional, Kalaycio, M., additional, Copelan, E., additional, Pohlman, B., additional, Dean, R., additional, Duong, H., additional, Hanna, R., additional, Maciejewski, J., additional, Bolwell, B., additional, and Sobecks, R., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results